IP Library › Granted Patent US 10,683,484
Granted Patent B2
US 10,683,484 · App. 15/735,321 · Granted Jun 16, 2020

Derivation of hepatic stem cells and mature liver cell types and uses thereof

Inventors: Yuanyu Hu (Singapore, SG); Huck Hui Ng (Singapore, SG); Yock Young Dan (Singapore, SG)
Assignees: NATIONAL UNIVERSITY OF SINGAPORE; AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
C12N5/0672A61K35/407A61P1/16C12N5/0037C12N5/067C12N5/0679
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,683,484
App. No.
15/735,321
Granted
Jun 16, 2020
Kind
B2
Abstract

This application describes liver stem cells (LSC), and differentiated hepatocytes, cholangiocytes, and 3D cellular structures derived therefrom. Methods for producing LSC and mature, differentiated hepatocytes and cholangiocytes in culture are provided. Also provided are cell culture systems and cell culture media for producing a homogenous population of liver stem cells that remain in an undifferentiated state over multiple passages in culture. The LSC and methods are useful for producing homogenous populations of hepatocytes and cholangiocytes for downstream applications. The LSC can be transplanted into subjects to treat liver diseases.

Claims (12)

1. A method of treating a subject having liver disease, comprising transplanting a human liver stem cell comprising the following characteristics into the liver of the subject:

(i) expresses at least 1, 2, 3 or 4 of the protein markers selected from SOX9, HNF4α, HNF3β, and EPCAM;

(ii) expresses low levels of KRT19 protein,

(iii) does not express detectable protein levels of KRT7 or AFP; and

(iv) does not have a polarized cell phenotype,

wherein the transplanted cell repopulates the liver of the subject, thereby treating the liver disease.

2. The method of claim 1 , wherein the liver disease is selected from the group of metabolic disease, autoimmune disease, infectious disease, drug induced acute and chronic liver failure, and liver cancer.

3. The method of claim 1 , wherein the liver stem cell further expresses 1, 2, 3, 4, or 5 protein markers selected from CD24, PROM1, FOXA3, FOXQ1 and ECAD.

4. The method of claim 1 , wherein the characteristics of the stem cell are maintained in long-term culture, and comprise a normal karyotype after 19 passages in culture.

5. The method of claim 1 , wherein the liver stem cell is a human fetal liver stem cell.

6. The method of claim 1 , wherein the liver stem cell is isolated from a healthy human subject.

7. The method of claim 1 , wherein the liver stem cell is isolated from a human subject with a liver disease, wherein the liver disease is selected from the group of metabolic disease, autoimmune disease, infectious disease, drug induced acute and chronic liver failure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2019
From: HU, YUANYU; NG, HUCK HUI
To: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Reel/Frame 051265/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2019
From: DAN, YOCK YOUNG
To: NATIONAL UNIVERSITY OF SINGAPORE
Reel/Frame 051265/0712 →
Priority Claims (2)
SG 10201504657Y · Jun 12, 2015 · national
SG 10201504659X · Jun 12, 2015 · national
Continuity (1)
Related Publication 20190161734A1 · May 30, 2019